An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and TB-500. The panel turned down emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may aid treatment of antibiotic-resistant bacteria. Meanwhile, Kennedy called for expanded access to controversial peptides, calling for reduced restrictions. The vote reflects a broader shift in how regulators view custom-mixed peptide therapies, which have drawn increasing interest from users seeking alternatives to standard drugs. Researchers say peptide treatments could alter approaches to difficult infections, though concerns about safety persist. The committee's endorsement of six peptides clears a path for more widespread prescribing, even as skeptics warn of limited evidence. Market watchers note that peptide-focused companies may see greater investor attention following the panel's decision. The rejection of emideltide, meanwhile, signals the FDA's cautious stance on certain peptide candidates.